CHFR and cancer: With the exemption of the EKVX NSCLC cell lines, synergy between ‘A3’ and docetaxel was observed for all other CHFR expressing cell lines regardless of tumor type supporting the possibility that CHFR targeted therapy may have a wide range of possible applications in those cancer types in which taxanes are frequently used (Figure 4C and 4E).